Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:EXEL
  • CUSIP: 30161Q10
  • Web: www.exelixis.com
Capitalization:
  • Market Cap: $7.85901 billion
  • Outstanding Shares: 293,904,000
Average Prices:
  • 50 Day Moving Avg: $26.26
  • 200 Day Moving Avg: $22.46
  • 52 Week Range: $10.04 - $28.45
P/E:
  • Trailing P/E Ratio: 135.91
  • Foreward P/E Ratio: 46.40
  • P/E Growth: 2.24
Sales & Book Value:
  • Annual Revenue: $319.67 million
  • Price / Sales: 24.74
  • Book Value: $0.51 per share
  • Price / Book: 52.76
Profitability:
  • EBIDTA: $95.32 million
  • Net Margins: 18.20%
  • Return on Equity: 80.43%
  • Return on Assets: 13.93%
Debt:
  • Current Ratio: 4.12%
  • Quick Ratio: 4.06%
Misc:
  • Average Volume: 4.26 million shs.
  • Beta: 1.89
  • Short Ratio: 3.04
 
Frequently Asked Questions for Exelixis (NASDAQ:EXEL)

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $99.01 million for the quarter, compared to analyst estimates of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. Exelixis's quarterly revenue was up 173.1% compared to the same quarter last year. During the same period last year, the company earned ($0.15) earnings per share. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Exelixis is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Exelixis.

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?

11 analysts have issued 1-year price targets for Exelixis' stock. Their predictions range from $15.00 to $33.00. On average, they anticipate Exelixis' stock price to reach $25.08 in the next year. View Analyst Ratings for Exelixis.

What are analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • 1. Cann analysts commented, "Exelixis, Inc. announced today a settlement of the company’s dispute with Genentech, a member of the Roche Group, concerning the parties’ collaboration for the development and commercialization of Cotellic (cobimetinib). As part of the settlement, effective July 1, 2017, the companies have amended the existing Collaboration Agreement to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016." (7/20/2017)
  • 2. According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in Apr 2016. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters in 2017. The sequential increase in Cabometyx sales is also a positive. Moreover, Cabometyx was also approved in the EU. Meanwhile, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. A potential label expansion will further boost sales. Exelixis also has collaborations with Bristol-Myers and Roche on the development of cabozantinib in combination with immunotherapy agents. Exelixis’ share price outperformed the Zacks classified Biomedical and Genetics industry year to date. However, the company is heavily dependent on Cabometyx for growth now.  Operating expenses are also projected to increase." (7/11/2017)

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
  • Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
  • Christopher J. Senner, Chief Financial Officer, Executive Vice President
  • Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
  • Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
  • Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
  • Patrick Haley, Senior Vice President - Commercial
  • Charles M. Cohen Ph.D., Independent Director
  • Carl B. Feldbaum Esq., Independent Director
  • Alan M. Garber M.D. Ph.D., Independent Director

Who owns Exelixis stock?

Exelixis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.89%), Vanguard Group Inc. (8.66%), Meditor Group Ltd (6.92%), BlackRock Inc. (5.16%), Matrix Capital Management Company LP (5.14%) and Goldman Sachs Group Inc. (2.40%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Farallon Capital Management LLC, Northern Trust Corp, Teachers Advisors LLC, State Street Corp, Acadian Asset Management LLC, Voya Investment Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Matrix Capital Management Company LP, Janus Henderson Group PLC, Meditor Group Ltd, Renaissance Technologies LLC, FMR LLC, Goldman Sachs Group Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Exelixis.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of Exelixis stock can currently be purchased for approximately $26.91.


MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  386
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $25.08 (6.80% downside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
8/3/2017Piper Jaffray CompaniesReiterated RatingBuy$29.00LowView Rating Details
8/3/2017Deutsche Bank AGDowngradeBuy -> Hold$26.00 -> $29.00MediumView Rating Details
8/3/2017Stifel NicolausReiterated RatingHold$26.00HighView Rating Details
7/27/2017William BlairReiterated RatingOutperformMediumView Rating Details
7/20/2017CannReiterated RatingHoldLowView Rating Details
7/13/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$33.00MediumView Rating Details
6/12/2017Oppenheimer Holdings, Inc.Initiated CoverageHoldLowView Rating Details
3/31/2017Needham & Company LLCInitiated CoverageBuy -> Buy$28.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
10/7/2016Leerink SwannReiterated RatingPositive$15.00N/AView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 8/16/2015 forward)

Earnings

Earnings History for Exelixis (NASDAQ:EXEL)
Earnings by Quarter for Exelixis (NASDAQ:EXEL)
Earnings History by Quarter for Exelixis (NASDAQ EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$0.05N/AView Earnings Details
8/2/2017Q2 2017$0.04$0.06$85.27 million$99.01 millionViewListenView Earnings Details
5/1/2017Q1 2017($0.01)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exelixis (NASDAQ:EXEL)
2017 EPS Consensus Estimate: $0.12
2018 EPS Consensus Estimate: $0.54
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)$0.01($0.01)
Q2 20174$0.01$0.03$0.02
Q3 20174$0.05$0.07$0.06
Q4 20174$0.04$0.07$0.06
Q1 20181$0.09$0.09$0.09
Q2 20181$0.10$0.10$0.10
Q3 20181$0.15$0.15$0.15
Q4 20181$0.20$0.20$0.20
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 79.93%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/30/2017Patrick J. HaleyInsiderSell5,000$18.46$92,300.00View SEC Filing  
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.04View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.50View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.00View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.50View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
Source:
DateHeadline
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Exelixis Inc.
finance.yahoo.com - August 14 at 11:57 PM
finance.yahoo.com logoIHS Markit Score upgrades Exelixis Inc to 72 out of 100, despite ranking positively in only one IHS Markit category.
finance.yahoo.com - August 11 at 7:00 PM
fool.com logoExelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts - Motley Fool
www.fool.com - August 9 at 11:44 PM
fool.com logoExelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts
www.fool.com - August 9 at 11:19 AM
americanbankingnews.com logoLeerink Swann Equities Analysts Cut Earnings Estimates for Exelixis, Inc. (NASDAQ:EXEL)
www.americanbankingnews.com - August 7 at 9:56 AM
americanbankingnews.com logoExelixis, Inc. Forecasted to Post Q1 2018 Earnings of $0.09 Per Share (NASDAQ:EXEL)
www.americanbankingnews.com - August 7 at 7:58 AM
americanbankingnews.com logoSunTrust Banks Brokers Increase Earnings Estimates for Exelixis, Inc. (EXEL)
www.americanbankingnews.com - August 7 at 7:46 AM
americanbankingnews.com logoExelixis, Inc. Expected to Earn Q3 2017 Earnings of $0.07 Per Share (EXEL)
www.americanbankingnews.com - August 7 at 7:08 AM
seekingalpha.com logoExelixis Earnings: Did The Market Respond Appropriately? - Seeking Alpha
seekingalpha.com - August 4 at 11:48 PM
fool.com logoExelixis, Inc. Grows Revenue, Eyes Treating More Patients - Motley Fool
www.fool.com - August 4 at 11:48 PM
americanbankingnews.com logoOppenheimer Holdings Analysts Increase Earnings Estimates for Exelixis, Inc. (NASDAQ:EXEL)
www.americanbankingnews.com - August 4 at 6:02 PM
fool.com logoExelixis, Inc. Grows Revenue, Eyes Treating More Patients
www.fool.com - August 4 at 3:10 PM
americanbankingnews.com logoExelixis, Inc. Forecasted to Earn Q3 2017 Earnings of $0.06 Per Share (EXEL)
www.americanbankingnews.com - August 4 at 8:02 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Exelixis, Inc. (EXEL) Boosted by William Blair
www.americanbankingnews.com - August 4 at 8:02 AM
americanbankingnews.com logoExelixis, Inc. to Post Q3 2017 Earnings of $0.05 Per Share, SunTrust Banks Forecasts (NASDAQ:EXEL)
www.americanbankingnews.com - August 4 at 8:02 AM
benzinga.com logoThe Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom - Benzinga
www.benzinga.com - August 4 at 1:28 AM
nasdaq.com logoExelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales ... - Nasdaq
www.nasdaq.com - August 4 at 1:28 AM
finance.yahoo.com logoThe Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom
finance.yahoo.com - August 3 at 8:27 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Releases Earnings Results
www.americanbankingnews.com - August 3 at 6:24 PM
fool.com logo3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance
www.fool.com - August 3 at 4:12 PM
zacks.com logoExelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales
www.zacks.com - August 3 at 3:26 PM
finance.yahoo.com logoDynavax Technologies Corporation (DVAX) Has the Market Buzzing with Heplisav Approval at the Finish Line, Exelixis, Inc. (EXEL) Refractory RCC Drug Going Strong in its Launch
finance.yahoo.com - August 3 at 3:26 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Rating Lowered to Hold at Deutsche Bank AG
www.americanbankingnews.com - August 3 at 8:56 AM
businesswire.com logoExelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update - Business Wire (press release)
www.businesswire.com - August 3 at 5:27 AM
finance.yahoo.com logoEdited Transcript of EXEL earnings conference call or presentation 2-Aug-17 9:00pm GMT
finance.yahoo.com - August 3 at 5:27 AM
seekingalpha.com logoExelixis (EXEL) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 12:25 AM
finance.yahoo.com logoExelixis tops Street 2Q forecasts
finance.yahoo.com - August 3 at 12:25 AM
finance.yahoo.com logoExelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 2 at 7:24 PM
seekingalpha.com logoExelixis beats by $0.02, beats on revenue
seekingalpha.com - August 2 at 4:15 PM
finance.yahoo.com logoExelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress
finance.yahoo.com - August 2 at 12:12 AM
businesswire.com logoExelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress - Business Wire (press release)
www.businesswire.com - August 1 at 7:09 PM
americanbankingnews.com logoExelixis, Inc. (NASDAQ:EXEL) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 1 at 8:58 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Exelixis, Inc. (NASDAQ:EXEL) Will Announce Quarterly Sales of $84.58 Million
www.americanbankingnews.com - August 1 at 8:05 AM
nasdaq.com logoCommit To Buy Exelixis At $17, Earn 11.5% Using Options - Nasdaq
www.nasdaq.com - July 31 at 6:14 PM
finance.yahoo.com logoImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up
finance.yahoo.com - July 31 at 6:14 PM
americanbankingnews.com logoZacks: Brokerages Expect Exelixis, Inc. (EXEL) Will Announce Earnings of $0.03 Per Share
www.americanbankingnews.com - July 30 at 6:25 PM
finance.yahoo.com logoGilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up
finance.yahoo.com - July 28 at 5:05 AM
americanbankingnews.com logoExelixis, Inc. (NASDAQ:EXEL) Rating Reiterated by William Blair
www.americanbankingnews.com - July 27 at 5:14 PM
marketwatch.com logoOpinion: Three biotech companies to watch ahead of earnings - MarketWatch
www.marketwatch.com - July 25 at 6:44 PM
bizjournals.com logoTechnical Snapshots for These Biotech Stocks -- Exelixis, Celldex Therapeutics, Clovis Oncology, and Geron
www.bizjournals.com - July 24 at 8:00 PM
zacks.com logoWhat's in the Cards for Exelixis (EXEL) in Q2 Earnings?
www.zacks.com - July 24 at 8:00 PM
finance.yahoo.com logoWhat's in the Cards for Exelixis (EXEL) in Q2 Earnings?
finance.yahoo.com - July 24 at 7:59 PM
americanbankingnews.com logoFY2019 Earnings Estimate for Exelixis, Inc. (NASDAQ:EXEL) Issued By Leerink Swann
www.americanbankingnews.com - July 24 at 11:30 AM
americanbankingnews.com logoFY2018 EPS Estimates for Exelixis, Inc. Raised by Leerink Swann (NASDAQ:EXEL)
www.americanbankingnews.com - July 21 at 3:32 PM
americanbankingnews.com logoFY2018 EPS Estimates for Exelixis, Inc. Lowered by William Blair (EXEL)
www.americanbankingnews.com - July 21 at 3:30 PM
finance.yahoo.com logoWilliam Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)
finance.yahoo.com - July 21 at 3:17 PM
finance.yahoo.com logo2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't
finance.yahoo.com - July 21 at 3:17 PM
streetinsider.com logoExelixis (EXEL), Genentech Reach Settlement in Dispute Regarding Companies' Collaboration Agreement for Cobimetinib
www.streetinsider.com - July 20 at 9:10 PM
reuters.com logoBRIEF-Exelixis announces settlement of dispute with Genentech
www.reuters.com - July 20 at 9:10 PM
businesswire.com logoExelixis Announces Settlement of Dispute with Genentech ... - Business Wire (press release)
www.businesswire.com - July 20 at 4:06 PM

Social

Chart

Exelixis (EXEL) Chart for Wednesday, August, 16, 2017

This page was last updated on 8/16/2017 by MarketBeat.com Staff